Biopharma News
Sage Therapeutics to Implement a 40% Workforce Reduction
Sage Therapeutics, Inc announced late last week plans to reorganise its business operations and pipeline priorities to support goals for long-term business growth. Read more
4 Sep 2023
IO Biotech Appoints Heidi Hunter to its Board of Directors
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, announced the appointment of Heidi Hunter to its board of directors. Read more
11 Aug 2023
Lytix Biopharma’s Licensing Partner Verrica Pharmaceuticals Reports Interim Phase 2 Data With LTX-315
Lytix Biopharma announces that its licensing partner Verrica Pharmaceuticals Inc has reported lesion clearance data from Part 1 of an ongoing Phase 2 study of VP-315 (formerly known as LTX 315) for the treatment of basal cell carcinoma (BCC). Read more
11 Aug 2023
Kincell Bio Launches with $36M to Make Cell Therapy Development and Manufacturing Accessible for Early-Stage Innovators
Kincell Bio, a technology-forward contract development and manufacturing organisation (CDMO) focused on cell therapies, emerged from stealth with $36 million in new funding. Read more
7 Aug 2023
AstraZeneca appoints Sharon Barr as Executive Vice President BioPharmaceuticals R&D
AstraZeneca today announced the appointment of Sharon Barr as Executive Vice President, BioPharmaceuticals R&D. Read more
4 Aug 2023
Trelleborg Launches BioPharmaPro Range
Trelleborg Healthcare and Medical launches the BioPharmaPro family of innovative products, materials and services for fluid path single-use equipment to accelerate the advancement of life-changing therapies. Read more
28 Jul 2023
Leqembi, Donanemab and Tofersen: The End of the Journey or the First Step on the Road to Reversing Neurodegeneration?
Dr. Peter Hamley, Chief Scientific Officer at Samsara Therapeutics, explores whether developments in therapeutics for neurodegenerative diseases are truly disease modifying or addressing the symptoms of a deeper problem. Read more
16 Aug 2023
R&D revolution: A new paradigm of sourcing and landscaping for the pharma industry
Dr Robin Knight, Co-Founder & Co-CEO of IN-PART, discusses the emerging importance of outsourcing landscaping activities within the pharmaceuticals industry and the benefits of adopting an openly innovative approach that pools sources of innovation. Read more
12 Jul 2023
Enhancing Biotherapeutic Properties with Cell-Line Engineering
Neha Mishra, Ph.D, Senior Scientist Bioproduction at Revvity explores enhancing biotherapeutic properties with cell-line engineering. Read more
30 Jun 2023
Trends in Solid Dosage Forms and their Challenges for R&D and Manufacture
CI Precision explore the trends in solid dosage forms and their challenges for R&D and manufacture. Read more
Orchard Therapeutics Receives FDA Approval of Lenmeldy
Orchard Therapeutics, recently acquired by Kyowa Kirin, have announced the U.S. FDA has approved Lenmeldy for the treatment of children with early-onset—metachromatic leukodystrophy. Read more
19 Mar 2024
Fusion Pharmaceuticals to be Acquired by AstraZeneca
Fusion Pharmaceuticals, a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, have announced the Company has entered into a definitive agreement to be acquired by AstraZeneca. Read more
19 Mar 2024
Pharma Manufacturing News + Pharma Finance and Investment News
Bluebird Bio Secures up to $175 Million Debt Financing
Bluebird Bio has entered into a $175 million five-year, term loan facility with Hercules Capital. The transaction strengthens the Company’s balance sheet as it executes on the commercial launches for its three FDA approved gene therapies. Read more
19 Mar 2024
Pharma Manufacturing News + Pharma Finance and Investment News
Novartis Invest $256 million in Singapore Biopharmaceutical Manufacturing Facility
Novartis recently announced it broke ground for the $256 million expansion of its biopharmaceutical manufacturing plant in Singapore. Read more
18 Mar 2024
Pharma Manufacturing News + Pharma Finance and Investment News
European Commission Approves Pfizer’s PREVENAR 20
Pfizer Inc have announced that the European Commission (EC) has granted marketing authorisation for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20. Read more
18 Mar 2024
Pharma Manufacturing News + Latest Pharmaceutical Manufacturing News
ReciBioPharm and GeneVentiv Therapeutics to Partner
ReciBioPharm, the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for haemophilia. Read more
18 Mar 2024
Pharma Manufacturing News + New Drug Development & Regulatory News
Sponsored Content
Trends in Solid Dosage Forms and their Challenges for R&D and Manufacture
CI Precision explore the trends in solid dosage forms and their challenges for R&D and manufacture. Read more
4 Mar 2024
09:25
Trends in Solid Dosage Forms and their Challenges for R&D and Manufacture
CI Precision explore the trends in solid dosage forms and their challenges for R&D and manufacture. Read more
Sponsored Content
Trends in Solid Dosage Forms and their Challenges for R&D and Manufacture
CI Precision explore the trends in solid dosage forms and their challenges for R&D and manufacture. Read more
4 Mar 2024
09:25